The Tapestri Single-cell Measurable Residual Disease (scMRD) Multiomics Assay for Acute Myeloid Leukemia (AML) is the only solution that simultaneously conducts and integrates the genotypic and immunophenotypic assessment of AML MRD across thousands of individual cells, providing clonal insight in tandem with immunophenotype from rare residual disease cells. These high-resolution, integrated molecular profiles bring unprecedented clarity to the complex biology of AML MRD, powering actionable insights. Learn more about the workflow, bioinformatics report, and assay content.
